tirzepatide surpass-5 Significantly Reduced A1C and Body Weight in People with Type 2 Diabetes in Two Phase 3 Trials from Lilly's SURPASS Program-CliniExpert Results of SURPASS-1-5 for tirzepatide

We currently intend to use the net proceeds from this offering and the concurrent private placement, together with our existing cash and cash equivalents as follows: Based on our current operating plan, we believe that our existing cash and cash equivalents, together with the net proceeds from this offering, will be sufficient for us to fund our operations into 2029

Foundayo (orforglipron) tablets Foundayo contains the active ingredient orforglipron , and is once-daily oral GLP-1 receptor agonist being developed by Eli Lilly

Approximately two-thirds of weight lost was regained within 12 months of discontinuation in participants who did not have established lifestyle support

Lee et al., 2017

Some people are looking for structured weight loss with medication

361-3E), in 85% to 100% of Asian neonates, more than 60% of black neonates, and less than 10% of white neonates